Literature DB >> 22212116

Profiling of humoral immune responses to influenza viruses by using protein microarray.

M Koopmans1, E de Bruin, G-J Godeke, I Friesema, R van Gageldonk, M Schipper, A Meijer, R van Binnendijk, G F Rimmelzwaan, M D de Jong, A Buisman, J van Beek, D van de Vijver, J Reimerink.   

Abstract

The emergence of pandemic A(H1N1) 2009 influenza showed the importance of rapid assessment of the degree of immunity in the population, the rate of asymptomatic infection, the spread of infection in households, effects of control measures, and ability of candidate vaccines to produce a response in different age groups. A limitation lies in the available assay repertoire: reference standard methods for measuring antibodies to influenza virus are haemagglutination inhibition (HI) assays and virus neutralization tests. Both assays are difficult to standardize and may be too specific to assess possible partial humoral immunity from previous exposures. Here, we describe the use of antigen-microarrays to measure antibodies to HA1 antigens from seven recent and historical seasonal H1, H2 and H3 influenza viruses, the A(H1N1) 2009 pandemic influenza virus, and three avian influenza viruses. We assessed antibody profiles in 18 adult patients infected with A(H1N1) 2009 influenza virus during the recent pandemic, and 21 children sampled before and after the pandemic, against background reactivity observed in 122 persons sampled in 2008, a season dominated by seasonal A(H1N1) influenza virus. We show that subtype-specific and variant-specific antibody responses can be measured, confirming serological responses measured by HI. Comparison of profiles from persons with similar HI response showed that the magnitude and broadness of response to individual influenza subtype antigens differs greatly between individuals. Clinical and vaccination studies, but also exposure studies, should take these findings into consideration, as they may indicate some level of humoral immunity not measured by HI assays.
© 2011 European Society of Clinical Microbiology and Infectious Diseases. No claim to original US government works.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212116     DOI: 10.1111/j.1469-0691.2011.03701.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  40 in total

1.  Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Authors:  Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

2.  Robust microarray production of freshly expressed proteins in a human milieu.

Authors:  Fernanda Festa; Sean M Rollins; Krishna Vattem; Margarita Hathaway; Phillip Lorenz; Eliseo A Mendoza; Xiaobo Yu; Ji Qiu; Greg Kilmer; Penny Jensen; Brian Webb; Ed T Ryan; Joshua LaBaer
Journal:  Proteomics Clin Appl       Date:  2013-05-17       Impact factor: 3.494

3.  Quantifying homologous and heterologous antibody titre rises after influenza virus infection.

Authors:  G Freeman; R A P M Perera; E Ngan; V J Fang; S Cauchemez; D K M Ip; J S M Peiris; B J Cowling
Journal:  Epidemiol Infect       Date:  2016-03-28       Impact factor: 2.451

4.  Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.

Authors:  Rory D de Vries; Arwen F Altenburg; Nella J Nieuwkoop; Erwin de Bruin; Stella E van Trierum; Mark R Pronk; Mart M Lamers; Mathilde Richard; David F Nieuwenhuijse; Marion P G Koopmans; Joost H C M Kreijtz; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

5.  Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.

Authors:  Muriel Aguilar-Bretones; Brenda M Westerhuis; Matthijs P Raadsen; Erwin de Bruin; Felicity D Chandler; Nisreen Ma Okba; Bart L Haagmans; Thomas Langerak; Henrik Endeman; Johannes Pc van den Akker; Diederik Ampj Gommers; Eric Cm van Gorp; Corine H GeurtsvanKessel; Rory D de Vries; Ron Am Fouchier; Barry Hg Rockx; Marion Pg Koopmans; Gijsbert P van Nierop
Journal:  J Clin Invest       Date:  2021-11-01       Impact factor: 14.808

6.  Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin.

Authors:  Robert P de Vries; Cornelis H Smit; Erwin de Bruin; Alan Rigter; Erik de Vries; Lisette A H M Cornelissen; Dirk Eggink; Nancy P Y Chung; John P Moore; Rogier W Sanders; Cornelis H Hokke; Marion Koopmans; Peter J M Rottier; Cornelis A M de Haan
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

7.  IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States.

Authors:  Zhu-Nan Li; Seh-Ching Lin; Paul J Carney; Ji Li; Feng Liu; Xiuhua Lu; Merry Liu; James Stevens; Min Levine; Jacqueline M Katz; Kathy Hancock
Journal:  Clin Vaccine Immunol       Date:  2014-05-28

8.  Performance of a multiplexed serological microarray for the detection of antibodies against central nervous system pathogens.

Authors:  Anne J Jääskeläinen; Sari M Viitala; Satu Kurkela; Satu Hepojoki; Heidi Sillanpää; Hannimari Kallio-Kokko; Tomas Bergström; Jukka Suni; Ale Närvänen; Olli Vapalahti; Antti Vaheri
Journal:  J Microbiol Methods       Date:  2014-03-01       Impact factor: 2.363

9.  Evaluation of multiplex assay platforms for detection of influenza hemagglutinin subtype specific antibody responses.

Authors:  Zhu-Nan Li; Kimberly M Weber; Rebecca A Limmer; Bobbi J Horne; James Stevens; Joy Schwerzmann; Jens Wrammert; Megan McCausland; Andrew J Phipps; Kathy Hancock; Daniel B Jernigan; Min Levine; Jacqueline M Katz; Joseph D Miller
Journal:  J Virol Methods       Date:  2017-01-17       Impact factor: 2.014

10.  Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach.

Authors:  Sophie van Tol; Ramona Mögling; Wentao Li; Gert-Jan Godeke; Arno Swart; Barbara Bergmans; Afke Brandenburg; Kristin Kremer; Jean-Luc Murk; Josine van Beek; Bas Wintermans; Johan Reimerink; Berend-Jan Bosch; Chantal Reusken
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.